One of the major causes of prostate cancer morbidity and mortality is bone metastases. Currently, when it comes to treating prostate cancer metastases we are very limited in effective therapies that actually prolong survival. Kirschenbaum A, etal (Departments of Urology and Medicine Division of Pulmonary Diseases Division of Endocrinology, Metabolism, and Bone Diseases, Mount Sinai [...]
Men who experience a reoccurrence post surgery will usually be referred for salvage radiation therapy. The goal of the radiation is to simply eliminate the stray cancer cells that might have remained in the prostate bed. The only way we currently have to monitor the outcomes from this radiation is to monitor PSA. Researchers at [...]
A lot has been written about the need to identify better biomarkers to both assist in the initial diagnosis of prostate cancer and then to help determine which cancers are potentially dangerous from those that are actually indolent. Finding these markers is vital, I too have written about the great need for them. However, in [...]
The May 5 issue of the Annals of Internal Medicine carried a report about some recent research looking to identify biomarkers for aggressive prostate cancer. We have been plagued with our inability to differentiate between which prostate cancers are aggressive and will kill and which are actually indolent and will not affect a man’s life. [...]